Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 1.00 |
| ▸ | MAOA | P21397 | 10/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599640 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2HTTPDE3B | |
| SCHEMBL18307137 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2HTTPDE3B | |
| SCHEMBL5751107 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2HTTPDE3B | |
| SCHEMBL299571 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2HTTPDE3B | |
| SCHEMBL3599644 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2HTTPDE3B | |
| SCHEMBL31469916 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2HTTPDE3B | |
| SCHEMBL279937 | 0.78 | EPHX2 (1.00) | MAOBMAOAEPHX2HTTPDE3B | |
| SCHEMBL4219649 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2HTTPDE3B | |
| SCHEMBL15630926 | 0.77 | MAOB (0.63) | MAOBMAOAEPHX2HTTPDE3B | |
| SCHEMBL3006703 | 0.77 | HTT (0.79) | MAOBMAOAEPHX2HTTPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174634-A1 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-30 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2022123039-A1 | ALDEHYDE DEHYDROGENASE INHIBITORS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-06-16 | — | — | WO | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-3027754-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | enEvolv, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017866-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| EP-1181282-A2 | BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000075139-A2 | BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-14 | — | — | WO | disclosed |
| US-6127360-A | ANTIHISTAMINES, ANTILEUKOTRIENES, ANTIINFLAMMATORY AGENTS, ANTIASTHMATIC AGENTS | KOWA CO., LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| US-6011033-A | ANTILEUKOTRIENIC ACTION AND ANTIHISTAMINIC ACTION | KOWA CO., LTD. (JP) | 2000-01-04 | — | — | US | disclosed |
| EP-0957100-A1 | DIAMINE DERIVATIVES AND PHARMACEUTICAL CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 1999-11-17 | — | — | EP | disclosed |
| US-5885987-A | ANTIHISTAMINE AGENT FOR TREATING ASTHMA, ANTILEUKOTRIENE AGENT, ANTIALLERGENS | KOWA CO., LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5756518-A | EXHIBITS ANTILEUKOTRIENIC ACTION AND ANTIHISTAMINIC ACTION; IS USEFUL IN TREATMENT OF ASTHMA | KOWA CO., LTD. (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0799826-A1 | Heteroaryl substituted phenylene derivatives, their preparation and their use as leukotriene receptor antagonists | KOWA CO. LTD. (JP) | 1997-10-08 | — | — | EP | disclosed |
| US-4535079-A | HYPOTENSIVE, ANTIARRHYTHMIA, ADRENERGIC BLOCKING AGENTS; VASODILATORS | MEDIOLANUM FARMACEUTICI S.R.L. (IT) | 1985-08-13 | — | — | US | disclosed |
| EP-0106816-A2 | Alkanolaminoxy derivatives of 3,4-dihydro-2H-1,4-benzothiazin-3-one, their production process, and their pharmaceutical use | MEDIOLANUM FARMACEUTICI s.r.l. (IT) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174634-A1 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | ALDH2, ALDH1A1, ALDH3A1 | MAOB 316/4885MAOA 246/4885EPHX2 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.